98%
921
2 minutes
20
Background: Blepharitis is a common eye disorder that may be overlooked by patients and clinical practitioners. The symptoms of blepharitis often manifest as irritation, a burning sensation, grittiness, and itchiness and may decrease visual acuity if not treated promptly. Meibomian gland dysfunction (MGD), a common cause of blepharitis, is believed to be associated with increased inflammatory marker levels that may disrupt the composition of lipids produced by the sebaceous glands in the eyelids and ultimately cause tear film instability.
Methods: This is a retrospective, population-based study using National Health Insurance Research Database (NHIRD) data from a 14-year period (2000-2015). Pearson chi-squared and Student's -tests were used to assess the differences in categorical and continuous variables, respectively, between statin users and non-statin users. Univariate and multivariate Cox regression analyses were performed to calculate the hazard ratios (HRs) after adjusting for confounders. Kaplan-Meier analysis was used to assess the cumulative risk of blepharitis between the two cohorts.
Results: A total of 67,014 patients who used statins were enrolled as the study cohort, and 268,056 patients who did not use statins were enrolled as the comparison cohort. The incidence of blepharitis was 3.04% with statin treatment and 3.72% without statin treatment ( < 0.001). Patients who used statins had a lower risk of developing blepharitis [adjusted hazard ratio (aHR): 0.746, < 0.001] than those who did not. In addition, diabetes mellitus (DM), hypertension, coronary heart disease (CHD), stroke, chalazion, rosacea, Sjogren syndrome, psoriasis and atopy were found to be possible risk factors for blepharitis.
Conclusion: Statin use can decrease the risk of developing blepharitis. However, further prospective studies are needed to evaluate statin treatment for various subtypes of blepharitis and to identify the associated mechanism.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965040 | PMC |
http://dx.doi.org/10.3389/fmed.2022.820119 | DOI Listing |
J Dement Alzheimers Dis
June 2025
Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02912, USA.
Background/objective: Cyclosporine A and other calcineurin inhibitors have been identified as prospective treatments for preventing Alzheimer's disease. We previously found that calcineurin inhibitors elicit a unique behavioral profile in zebrafish larvae, characterized by increased activity, acoustic hyperexcitability, and reduced visually guided behaviors. Screening a large library of FDA-approved compounds using Z-LaP Tracker revealed that some heart medications produce a similar behavioral profile, suggesting these drugs may exert calcineurin-inhibitor-like effects relevant to prevent-ing or ameliorating Alzheimer's disease.
View Article and Find Full Text PDFRev Cardiovasc Med
August 2025
Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, 100029 Beijing, China.
Background: The incidence of unstable angina (UA), a type of cardiovascular disease (CVD), has increased in recent years. Meanwhile, timely percutaneous coronary intervention (PCI) or percutaneous transluminal coronary angioplasty (PTCA) procedures are crucial for patients with UA who also have diabetes mellitus (DM). Additionally, exploring other factors that may influence the prognosis of these patients could provide long-term benefits.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background: Acute myocardial infarction (AMI) patients with prior malignancy have been largely understudied, despite potentially facing higher risks of adverse outcomes. This case-control study aimed to identify independent risk factors for in-hospital mechanical complications among AMI patients with prior malignancies.
Methods: This study enrolled AMI patients with prior malignancy who were hospitalized for treatment.
Turk Kardiyol Dern Ars
September 2025
Department of Cardiology, Koç University School of Medicine, Istanbul, Türkiye.
Objective: Coronary artery calcification (CAC) and osteoporosis are common age-related conditions that may share underlying mechanisms such as inflammation and lipid dysregulation. Lipoprotein(a) [Lp(a)] has been suggested as a potential contributor to both processes. This study aims to investigate the relationship between CAC, bone mineral density (BMD), and Lp(a) levels in a statin-naive elderly population.
View Article and Find Full Text PDFInt J Med Inform
September 2025
Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:
Background: Identifying patient-specific barriers to statin therapy, such as intolerance or deferral, from clinical notes is a major challenge for improving cardiovascular care. Automating this process could enable targeted interventions and improve clinical decision support (CDS).
Objective: To develop and evaluate a novel hybrid artificial intelligence (AI) framework for accurately and efficiently extracting information on statin therapy barriers from large volumes of clinical notes.